Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Morren

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cleveland Clinic Journal of Medicine|February 1, 2023
What are the treatment options for myasthenia gravis if first-line agents fail?Christopher Zust, John A Morren
Cleveland Clinic Journal of Medicine|February 1, 2023
Myasthenia gravis: Frequently asked questionsJohn A Morren, Yuebing Li
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|January 17, 2012
Stroke literacy, behavior, and proficiency in a South Florida populationJohn A Morren, Efrain D Salgado
Expert Opinion on Investigational Drugs|February 7, 2012
Current and prospective disease-modifying therapies for amyotrophic lateral sclerosisJohn A Morren, Nestor Galvez-Jimenez
Expert Opinion on Pharmacotherapy|November 18, 2010
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?John A Morren, Nestor Galvez-Jimenez
The International Journal of Neuroscience|August 18, 2012
Prevalence and control of stroke risk factors in a South Florida populationJohn A Morren, Efrain D Salgado
Expert Opinion on Pharmacotherapy|March 25, 2024
Promising therapies for the treatment of myasthenia gravisSanem Pinar Uysal, John A Morren
Expert Opinion on Investigational Drugs|August 29, 2023
CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)J Daniel Bireley, John A Morren
Muscle & Nerve|October 26, 2019
Utility of electrodiagnostic studies in patients referred with a diagnosis of polyneuropathyMatthew R Ginsberg, John A Morren
Muscle & Nerve|December 27, 2023
The role of artificial intelligence in electrodiagnostic and neuromuscular medicine: Current state and future directionsMohamed A Taha, John A Morren
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cleveland Clinic Journal of Medicine|February 1, 2023
What are the treatment options for myasthenia gravis if first-line agents fail?Christopher Zust, John A Morren
Cleveland Clinic Journal of Medicine|February 1, 2023
Myasthenia gravis: Frequently asked questionsJohn A Morren, Yuebing Li
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|January 17, 2012
Stroke literacy, behavior, and proficiency in a South Florida populationJohn A Morren, Efrain D Salgado
Expert Opinion on Investigational Drugs|February 7, 2012
Current and prospective disease-modifying therapies for amyotrophic lateral sclerosisJohn A Morren, Nestor Galvez-Jimenez
Expert Opinion on Pharmacotherapy|November 18, 2010
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?John A Morren, Nestor Galvez-Jimenez
The International Journal of Neuroscience|August 18, 2012
Prevalence and control of stroke risk factors in a South Florida populationJohn A Morren, Efrain D Salgado
Expert Opinion on Pharmacotherapy|March 25, 2024
Promising therapies for the treatment of myasthenia gravisSanem Pinar Uysal, John A Morren
Expert Opinion on Investigational Drugs|August 29, 2023
CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)J Daniel Bireley, John A Morren
Muscle & Nerve|October 26, 2019
Utility of electrodiagnostic studies in patients referred with a diagnosis of polyneuropathyMatthew R Ginsberg, John A Morren
Muscle & Nerve|December 27, 2023
The role of artificial intelligence in electrodiagnostic and neuromuscular medicine: Current state and future directionsMohamed A Taha, John A Morren
Pageof 2